The Upfront Review Clerk is responsible for the quality review of all pertinent customer information for accuracy and completeness in order to meet payer requirements for timely and maximum reimbursement.
(Administrative Support / Clerical / Medical Clerk / Office Support)
ESSENTIAL DUTIES AND RESPONSIBILITIES include the following (other tasks may be assigned):
Evaluate all received documents to ensure that appropriate information has been obtained to allow for successful Accounts Receivable
Maintain Held Sales by assisting customer service representatives weekly in correcting problems so billing may begin or continue
Responsible for reviewing various reports for quality assurance
Record all activity relating to the account in tickler files
Requirements:
High school diploma or general education degree (GED)
Knowledge of the medical field preferred
Computer literacy, keyboarding skills, and proficiency in the use of office equipment
Knowledge of telephone etiquette and adequate oral and written communication skills
Must be 18 years of age or older
Jul 22, 2019
The Upfront Review Clerk is responsible for the quality review of all pertinent customer information for accuracy and completeness in order to meet payer requirements for timely and maximum reimbursement.
(Administrative Support / Clerical / Medical Clerk / Office Support)
ESSENTIAL DUTIES AND RESPONSIBILITIES include the following (other tasks may be assigned):
Evaluate all received documents to ensure that appropriate information has been obtained to allow for successful Accounts Receivable
Maintain Held Sales by assisting customer service representatives weekly in correcting problems so billing may begin or continue
Responsible for reviewing various reports for quality assurance
Record all activity relating to the account in tickler files
Requirements:
High school diploma or general education degree (GED)
Knowledge of the medical field preferred
Computer literacy, keyboarding skills, and proficiency in the use of office equipment
Knowledge of telephone etiquette and adequate oral and written communication skills
Must be 18 years of age or older
Job Purpose:
To manage Seqirus business at Public Health accounts within broad regional territories, including Public Health Departments, State Immunization Projects, Federally Qualified Health Centers, Disproportionate Share (340B) Hospitals, District, County and Local Health Departments/Districts. To initiate and grow Seqirus’ entry into pediatric focused customers; to initiate and execute account plans that will allow penetration, retention and growth within key customer segments; to support and oversee successful communication and brand promotion.
Regional Account Manager, Public Health acts as the primary point of contact for Seqirus for a defined set of accounts (~30 accounts within their territory), analyzing and understanding sales trends for product sales to each account, achieving defined goals and objectives, and promoting a mutually beneficial business relationship while adhering to Seqirus Core Values.
Works closely with Director, Public Health Account Management as well as National Accounts, Regional Accounts and Field based sales teams to establish & execute tactical initiatives reflected in dedicated business plans, which align with the Americas & US influenza business unit objectives.
Responsible for cultivating a close relationship with cross functional team colleagues in Sales, Medical Affairs, Marketing, Distribution / Logistics, Customer Service, and Public Affairs departments to implement corporate, market access and brand specific strategies and tactics.
Major Accountabilities:
Drives sales results to achieve / exceed specific sales volume, revenue, and profitability targets.
Acts as the primary point of contact for Seqirus with assigned accounts. Fosters and develops multi-level and senior relationships to create a foundation for developing new business opportunities.
Manages relationships with key stakeholders and influences the choice of Seqirus portfolio
Develops strategy and execution plan to drive growth in specific region public programs, including the leveraging of Direct and Indirect selling efforts
Analyzes accounts’ near-term and longer-term objectives and promotes consideration of company products and services to meet and align with identified objectives. Reports timely feedback regarding account trends and anticipated impact on sales. Provide timely and accurate forecast for each assigned account. Develops strategic and tactical planning for both the Vaccines for Children Program and Vaccines for Adult program within assigned accounts.
With relationship depth and breadth of customer interaction at various (senior management clinical / financial / operational) levels of the customer’s organization, builds and maintains relationships with key individuals to enable market access of Seqirus vaccines, developing a favorable environment for pull-through at the national, regional, and local provider levels. Develops and sponsors key programs which address customer needs and enhances the customer value perception of Seqirus.
Represents the Seqirus Customer Experience vision internally and externally; Acts as the voice of the customer with internal stakeholders to build Seqirus’ acumen on customer challenges; Develops and executes business solutions at customers that help enhance Seqirus’ partnership within Seqirus primary channels.
Works with internal and external stakeholders to enhance Seqirus position in the market
Represents Seqirus at key trade and customer meetings / conferences. Coordinates customer training and in-services with Medical Affairs.
Works with National and Regional Accounts Team to troubleshoot specific accounts to overcome reimbursement issues and barriers involving the Seqirus product portfolio.
Collaborates with appropriate Seqirus business teams, marketing, and medical affairs to ensure alignment and full utilization of resources at account level. This includes utilization of marketing materials, execution of in-services, development and execution of marketing or other service agreements.
Liaises with Contracts, Customer Operations, Commercial Policy, Legal, HR, and Finance to ensure successful outcomes for the responsible channels
Uses available resources to improve regional account management and liaises with Marketing teams to develop pull-through plans and value-added service offerings
Minimum Requirements:
Bachelor’s Degree in Business, Health Policy, Life Sciences or equivalent years’ experience
A proven track record of successful account management demonstrated though relationship building within the public health sector
Experience in executing strategies with public health accounts through cross-functional teams for immunizations
Minimum of 4 years vaccines sales experience/6 years B2B or Pharma equivalent sales
Prior Vaccine Account Management/State Health Project experience highly preferred
Jul 17, 2019
Job Purpose:
To manage Seqirus business at Public Health accounts within broad regional territories, including Public Health Departments, State Immunization Projects, Federally Qualified Health Centers, Disproportionate Share (340B) Hospitals, District, County and Local Health Departments/Districts. To initiate and grow Seqirus’ entry into pediatric focused customers; to initiate and execute account plans that will allow penetration, retention and growth within key customer segments; to support and oversee successful communication and brand promotion.
Regional Account Manager, Public Health acts as the primary point of contact for Seqirus for a defined set of accounts (~30 accounts within their territory), analyzing and understanding sales trends for product sales to each account, achieving defined goals and objectives, and promoting a mutually beneficial business relationship while adhering to Seqirus Core Values.
Works closely with Director, Public Health Account Management as well as National Accounts, Regional Accounts and Field based sales teams to establish & execute tactical initiatives reflected in dedicated business plans, which align with the Americas & US influenza business unit objectives.
Responsible for cultivating a close relationship with cross functional team colleagues in Sales, Medical Affairs, Marketing, Distribution / Logistics, Customer Service, and Public Affairs departments to implement corporate, market access and brand specific strategies and tactics.
Major Accountabilities:
Drives sales results to achieve / exceed specific sales volume, revenue, and profitability targets.
Acts as the primary point of contact for Seqirus with assigned accounts. Fosters and develops multi-level and senior relationships to create a foundation for developing new business opportunities.
Manages relationships with key stakeholders and influences the choice of Seqirus portfolio
Develops strategy and execution plan to drive growth in specific region public programs, including the leveraging of Direct and Indirect selling efforts
Analyzes accounts’ near-term and longer-term objectives and promotes consideration of company products and services to meet and align with identified objectives. Reports timely feedback regarding account trends and anticipated impact on sales. Provide timely and accurate forecast for each assigned account. Develops strategic and tactical planning for both the Vaccines for Children Program and Vaccines for Adult program within assigned accounts.
With relationship depth and breadth of customer interaction at various (senior management clinical / financial / operational) levels of the customer’s organization, builds and maintains relationships with key individuals to enable market access of Seqirus vaccines, developing a favorable environment for pull-through at the national, regional, and local provider levels. Develops and sponsors key programs which address customer needs and enhances the customer value perception of Seqirus.
Represents the Seqirus Customer Experience vision internally and externally; Acts as the voice of the customer with internal stakeholders to build Seqirus’ acumen on customer challenges; Develops and executes business solutions at customers that help enhance Seqirus’ partnership within Seqirus primary channels.
Works with internal and external stakeholders to enhance Seqirus position in the market
Represents Seqirus at key trade and customer meetings / conferences. Coordinates customer training and in-services with Medical Affairs.
Works with National and Regional Accounts Team to troubleshoot specific accounts to overcome reimbursement issues and barriers involving the Seqirus product portfolio.
Collaborates with appropriate Seqirus business teams, marketing, and medical affairs to ensure alignment and full utilization of resources at account level. This includes utilization of marketing materials, execution of in-services, development and execution of marketing or other service agreements.
Liaises with Contracts, Customer Operations, Commercial Policy, Legal, HR, and Finance to ensure successful outcomes for the responsible channels
Uses available resources to improve regional account management and liaises with Marketing teams to develop pull-through plans and value-added service offerings
Minimum Requirements:
Bachelor’s Degree in Business, Health Policy, Life Sciences or equivalent years’ experience
A proven track record of successful account management demonstrated though relationship building within the public health sector
Experience in executing strategies with public health accounts through cross-functional teams for immunizations
Minimum of 4 years vaccines sales experience/6 years B2B or Pharma equivalent sales
Prior Vaccine Account Management/State Health Project experience highly preferred
With operations in 35+ nations and ~ 22,000 employees worldwide, CSL is driven to develop and deliver a broad range of lifesaving therapies to treat disorders such as hemophilia and primary immune deficiencies, and vaccines to prevent influenza. Our therapies are also used in cardiac surgery, organ transplantation and burn treatment.
CSL is the parent company of CSL Behring and Seqirus. CSL Behring is a global leader in the protein biotherapeutics industry, focused on bringing to market biotherapies used to treat serious and often rare conditions. CSL Behring operates CSL Plasma , one of the world's largest collectors of human plasma, which is used to create CSL’s therapies. Seqirus is the second largest influenza vaccine company in the world and is a transcontinental partner in pandemic preparedness and a major contributor to the prevention and control of influenza globally.
We invite you to take a look at the many career possibilities available around the globe and consider building your promising future at CSL by becoming a member of our team!
All qualified applicants will receive consideration for employment without regard to race, color, religion, sex, sexual orientation, gender identity, disability, veteran status, national origin or other legally protected classifications.
Jul 17, 2019
With operations in 35+ nations and ~ 22,000 employees worldwide, CSL is driven to develop and deliver a broad range of lifesaving therapies to treat disorders such as hemophilia and primary immune deficiencies, and vaccines to prevent influenza. Our therapies are also used in cardiac surgery, organ transplantation and burn treatment.
CSL is the parent company of CSL Behring and Seqirus. CSL Behring is a global leader in the protein biotherapeutics industry, focused on bringing to market biotherapies used to treat serious and often rare conditions. CSL Behring operates CSL Plasma , one of the world's largest collectors of human plasma, which is used to create CSL’s therapies. Seqirus is the second largest influenza vaccine company in the world and is a transcontinental partner in pandemic preparedness and a major contributor to the prevention and control of influenza globally.
We invite you to take a look at the many career possibilities available around the globe and consider building your promising future at CSL by becoming a member of our team!
All qualified applicants will receive consideration for employment without regard to race, color, religion, sex, sexual orientation, gender identity, disability, veteran status, national origin or other legally protected classifications.
With operations in 35+ nations and ~ 22,000 employees worldwide, CSL is driven to develop and deliver a broad range of lifesaving therapies to treat disorders such as hemophilia and primary immune deficiencies, and vaccines to prevent influenza. Our therapies are also used in cardiac surgery, organ transplantation and burn treatment.
CSL is the parent company of CSL Behring and Seqirus. CSL Behring is a global leader in the protein biotherapeutics industry, focused on bringing to market biotherapies used to treat serious and often rare conditions. CSL Behring operates CSL Plasma , one of the world's largest collectors of human plasma, which is used to create CSL’s therapies. Seqirus is the second largest influenza vaccine company in the world and is a transcontinental partner in pandemic preparedness and a major contributor to the prevention and control of influenza globally.
We invite you to take a look at the many career possibilities available around the globe and consider building your promising future at CSL by becoming a member of our team!
All qualified applicants will receive consideration for employment without regard to race, color, religion, sex, sexual orientation, gender identity, disability, veteran status, national origin or other legally protected classifications.
Jul 17, 2019
With operations in 35+ nations and ~ 22,000 employees worldwide, CSL is driven to develop and deliver a broad range of lifesaving therapies to treat disorders such as hemophilia and primary immune deficiencies, and vaccines to prevent influenza. Our therapies are also used in cardiac surgery, organ transplantation and burn treatment.
CSL is the parent company of CSL Behring and Seqirus. CSL Behring is a global leader in the protein biotherapeutics industry, focused on bringing to market biotherapies used to treat serious and often rare conditions. CSL Behring operates CSL Plasma , one of the world's largest collectors of human plasma, which is used to create CSL’s therapies. Seqirus is the second largest influenza vaccine company in the world and is a transcontinental partner in pandemic preparedness and a major contributor to the prevention and control of influenza globally.
We invite you to take a look at the many career possibilities available around the globe and consider building your promising future at CSL by becoming a member of our team!
All qualified applicants will receive consideration for employment without regard to race, color, religion, sex, sexual orientation, gender identity, disability, veteran status, national origin or other legally protected classifications.
With operations in 35+ nations and ~ 22,000 employees worldwide, CSL is driven to develop and deliver a broad range of lifesaving therapies to treat disorders such as hemophilia and primary immune deficiencies, and vaccines to prevent influenza. Our therapies are also used in cardiac surgery, organ transplantation and burn treatment.
CSL is the parent company of CSL Behring and Seqirus. CSL Behring is a global leader in the protein biotherapeutics industry, focused on bringing to market biotherapies used to treat serious and often rare conditions. CSL Behring operates CSL Plasma , one of the world's largest collectors of human plasma, which is used to create CSL’s therapies. Seqirus is the second largest influenza vaccine company in the world and is a transcontinental partner in pandemic preparedness and a major contributor to the prevention and control of influenza globally.
We invite you to take a look at the many career possibilities available around the globe and consider building your promising future at CSL by becoming a member of our team!
All qualified applicants will receive consideration for employment without regard to race, color, religion, sex, sexual orientation, gender identity, disability, veteran status, national origin or other legally protected classifications.
Jul 17, 2019
With operations in 35+ nations and ~ 22,000 employees worldwide, CSL is driven to develop and deliver a broad range of lifesaving therapies to treat disorders such as hemophilia and primary immune deficiencies, and vaccines to prevent influenza. Our therapies are also used in cardiac surgery, organ transplantation and burn treatment.
CSL is the parent company of CSL Behring and Seqirus. CSL Behring is a global leader in the protein biotherapeutics industry, focused on bringing to market biotherapies used to treat serious and often rare conditions. CSL Behring operates CSL Plasma , one of the world's largest collectors of human plasma, which is used to create CSL’s therapies. Seqirus is the second largest influenza vaccine company in the world and is a transcontinental partner in pandemic preparedness and a major contributor to the prevention and control of influenza globally.
We invite you to take a look at the many career possibilities available around the globe and consider building your promising future at CSL by becoming a member of our team!
All qualified applicants will receive consideration for employment without regard to race, color, religion, sex, sexual orientation, gender identity, disability, veteran status, national origin or other legally protected classifications.
Know that there are people behind the data. Patients and Physicians rely on our diagnostic testing, information and services to help them make better healthcare decisions. These are often serious decisions with far reaching consequences, and require sensitivity, tact and a clear dedication to service. It’s about providing clarity and hope.
In Logistics you will work for the world leader in the industry, with a career where you can expand your skills and knowledge. You’ll have a role where you can act with professionalism, you can inspire colleagues, and you can care about the work we do and the people we serve.
At Quest, our Logistics personnel are critical to the people we serve – your fast, safe and efficient transportation is an important step in diagnoses and treatment. As a career, it offers variety and a certain amount of independent working – with the added bonus of meeting and dealing with a variety of people in your day. Joining a diverse team, a Logistics role can offer you a stable, long-term career.
All requirements are subject to possible modifications to reasonably accommodate individuals with disabilities. Quest Diagnostics is an Equal Opportunity Employer: Women / Minorities / Veterans / Disabled / Sexual Orientation / Gender Identity or Citizenship.
Jul 15, 2019
Know that there are people behind the data. Patients and Physicians rely on our diagnostic testing, information and services to help them make better healthcare decisions. These are often serious decisions with far reaching consequences, and require sensitivity, tact and a clear dedication to service. It’s about providing clarity and hope.
In Logistics you will work for the world leader in the industry, with a career where you can expand your skills and knowledge. You’ll have a role where you can act with professionalism, you can inspire colleagues, and you can care about the work we do and the people we serve.
At Quest, our Logistics personnel are critical to the people we serve – your fast, safe and efficient transportation is an important step in diagnoses and treatment. As a career, it offers variety and a certain amount of independent working – with the added bonus of meeting and dealing with a variety of people in your day. Joining a diverse team, a Logistics role can offer you a stable, long-term career.
All requirements are subject to possible modifications to reasonably accommodate individuals with disabilities. Quest Diagnostics is an Equal Opportunity Employer: Women / Minorities / Veterans / Disabled / Sexual Orientation / Gender Identity or Citizenship.
Celgene is committed to advancing research to deliver life-changing solutions for people living with a wide range of debilitating and chronic diseases, including Multiple Sclerosis (MS). Our teams and experts in the field share our excitement for what we’re doing now and what lies ahead for MS and the global community to improve the lives of over 2.5 million people around the globe with this autoimmune, neuroinflammatory disease.
COMMITTED TO IMPROVING THE LIVES OF PATIENTS WORLDWIDE
At Celgene, we seek to deliver truly innovative and life-changing drugs for our patients. Our vision as a company is to build a major global biopharmaceutical corporation while focusing on the discovery, the development, and the commercialization of products for the treatment of cancer and other severe, immune, inflammatory conditions.
There are more than 300 clinical trials at major medical centers using compounds from Celgene. Investigational compounds are being studied for patients with incurable hematological and solid tumor cancers, including multiple myeloma, myelodysplastic syndromes, chronic lymphocytic leukemia (CLL), non-Hodgkin’s lymphoma (NHL), triple-negative breast cancer and pancreatic cancer. As committed as we are to clinical accomplishment, we are equally committed to patient support, which is a guiding principle at Celgene. We believe all who can benefit from our discoveries should have the opportunity to do so. Celgene puts patients first with industry-leading programs that provide information, support and access to our innovative therapies.
Jul 02, 2019
Celgene is committed to advancing research to deliver life-changing solutions for people living with a wide range of debilitating and chronic diseases, including Multiple Sclerosis (MS). Our teams and experts in the field share our excitement for what we’re doing now and what lies ahead for MS and the global community to improve the lives of over 2.5 million people around the globe with this autoimmune, neuroinflammatory disease.
COMMITTED TO IMPROVING THE LIVES OF PATIENTS WORLDWIDE
At Celgene, we seek to deliver truly innovative and life-changing drugs for our patients. Our vision as a company is to build a major global biopharmaceutical corporation while focusing on the discovery, the development, and the commercialization of products for the treatment of cancer and other severe, immune, inflammatory conditions.
There are more than 300 clinical trials at major medical centers using compounds from Celgene. Investigational compounds are being studied for patients with incurable hematological and solid tumor cancers, including multiple myeloma, myelodysplastic syndromes, chronic lymphocytic leukemia (CLL), non-Hodgkin’s lymphoma (NHL), triple-negative breast cancer and pancreatic cancer. As committed as we are to clinical accomplishment, we are equally committed to patient support, which is a guiding principle at Celgene. We believe all who can benefit from our discoveries should have the opportunity to do so. Celgene puts patients first with industry-leading programs that provide information, support and access to our innovative therapies.
Celgene is committed to advancing research to deliver life-changing solutions for people living with a wide range of debilitating and chronic diseases, including Multiple Sclerosis (MS). Our teams and experts in the field share our excitement for what we’re doing now and what lies ahead for MS and the global community to improve the lives of over 2.5 million people around the globe with this autoimmune, neuroinflammatory disease.
COMMITTED TO IMPROVING THE LIVES OF PATIENTS WORLDWIDE
At Celgene, we seek to deliver truly innovative and life-changing drugs for our patients. Our vision as a company is to build a major global biopharmaceutical corporation while focusing on the discovery, the development, and the commercialization of products for the treatment of cancer and other severe, immune, inflammatory conditions.
There are more than 300 clinical trials at major medical centers using compounds from Celgene. Investigational compounds are being studied for patients with incurable hematological and solid tumor cancers, including multiple myeloma, myelodysplastic syndromes, chronic lymphocytic leukemia (CLL), non-Hodgkin’s lymphoma (NHL), triple-negative breast cancer and pancreatic cancer. As committed as we are to clinical accomplishment, we are equally committed to patient support, which is a guiding principle at Celgene. We believe all who can benefit from our discoveries should have the opportunity to do so. Celgene puts patients first with industry-leading programs that provide information, support and access to our innovative therapies.
Jul 02, 2019
Celgene is committed to advancing research to deliver life-changing solutions for people living with a wide range of debilitating and chronic diseases, including Multiple Sclerosis (MS). Our teams and experts in the field share our excitement for what we’re doing now and what lies ahead for MS and the global community to improve the lives of over 2.5 million people around the globe with this autoimmune, neuroinflammatory disease.
COMMITTED TO IMPROVING THE LIVES OF PATIENTS WORLDWIDE
At Celgene, we seek to deliver truly innovative and life-changing drugs for our patients. Our vision as a company is to build a major global biopharmaceutical corporation while focusing on the discovery, the development, and the commercialization of products for the treatment of cancer and other severe, immune, inflammatory conditions.
There are more than 300 clinical trials at major medical centers using compounds from Celgene. Investigational compounds are being studied for patients with incurable hematological and solid tumor cancers, including multiple myeloma, myelodysplastic syndromes, chronic lymphocytic leukemia (CLL), non-Hodgkin’s lymphoma (NHL), triple-negative breast cancer and pancreatic cancer. As committed as we are to clinical accomplishment, we are equally committed to patient support, which is a guiding principle at Celgene. We believe all who can benefit from our discoveries should have the opportunity to do so. Celgene puts patients first with industry-leading programs that provide information, support and access to our innovative therapies.
Celgene is committed to advancing research to deliver life-changing solutions for people living with a wide range of debilitating and chronic diseases, including Multiple Sclerosis (MS). Our teams and experts in the field share our excitement for what we’re doing now and what lies ahead for MS and the global community to improve the lives of over 2.5 million people around the globe with this autoimmune, neuroinflammatory disease.
COMMITTED TO IMPROVING THE LIVES OF PATIENTS WORLDWIDE
At Celgene, we seek to deliver truly innovative and life-changing drugs for our patients. Our vision as a company is to build a major global biopharmaceutical corporation while focusing on the discovery, the development, and the commercialization of products for the treatment of cancer and other severe, immune, inflammatory conditions.
There are more than 300 clinical trials at major medical centers using compounds from Celgene. Investigational compounds are being studied for patients with incurable hematological and solid tumor cancers, including multiple myeloma, myelodysplastic syndromes, chronic lymphocytic leukemia (CLL), non-Hodgkin’s lymphoma (NHL), triple-negative breast cancer and pancreatic cancer. As committed as we are to clinical accomplishment, we are equally committed to patient support, which is a guiding principle at Celgene. We believe all who can benefit from our discoveries should have the opportunity to do so. Celgene puts patients first with industry-leading programs that provide information, support and access to our innovative therapies.
Jul 02, 2019
Celgene is committed to advancing research to deliver life-changing solutions for people living with a wide range of debilitating and chronic diseases, including Multiple Sclerosis (MS). Our teams and experts in the field share our excitement for what we’re doing now and what lies ahead for MS and the global community to improve the lives of over 2.5 million people around the globe with this autoimmune, neuroinflammatory disease.
COMMITTED TO IMPROVING THE LIVES OF PATIENTS WORLDWIDE
At Celgene, we seek to deliver truly innovative and life-changing drugs for our patients. Our vision as a company is to build a major global biopharmaceutical corporation while focusing on the discovery, the development, and the commercialization of products for the treatment of cancer and other severe, immune, inflammatory conditions.
There are more than 300 clinical trials at major medical centers using compounds from Celgene. Investigational compounds are being studied for patients with incurable hematological and solid tumor cancers, including multiple myeloma, myelodysplastic syndromes, chronic lymphocytic leukemia (CLL), non-Hodgkin’s lymphoma (NHL), triple-negative breast cancer and pancreatic cancer. As committed as we are to clinical accomplishment, we are equally committed to patient support, which is a guiding principle at Celgene. We believe all who can benefit from our discoveries should have the opportunity to do so. Celgene puts patients first with industry-leading programs that provide information, support and access to our innovative therapies.
Celgene is committed to advancing research to deliver life-changing solutions for people living with a wide range of debilitating and chronic diseases, including Multiple Sclerosis (MS). Our teams and experts in the field share our excitement for what we’re doing now and what lies ahead for MS and the global community to improve the lives of over 2.5 million people around the globe with this autoimmune, neuroinflammatory disease.
COMMITTED TO IMPROVING THE LIVES OF PATIENTS WORLDWIDE
At Celgene, we seek to deliver truly innovative and life-changing drugs for our patients. Our vision as a company is to build a major global biopharmaceutical corporation while focusing on the discovery, the development, and the commercialization of products for the treatment of cancer and other severe, immune, inflammatory conditions.
There are more than 300 clinical trials at major medical centers using compounds from Celgene. Investigational compounds are being studied for patients with incurable hematological and solid tumor cancers, including multiple myeloma, myelodysplastic syndromes, chronic lymphocytic leukemia (CLL), non-Hodgkin’s lymphoma (NHL), triple-negative breast cancer and pancreatic cancer. As committed as we are to clinical accomplishment, we are equally committed to patient support, which is a guiding principle at Celgene. We believe all who can benefit from our discoveries should have the opportunity to do so. Celgene puts patients first with industry-leading programs that provide information, support and access to our innovative therapies.
Jul 02, 2019
Celgene is committed to advancing research to deliver life-changing solutions for people living with a wide range of debilitating and chronic diseases, including Multiple Sclerosis (MS). Our teams and experts in the field share our excitement for what we’re doing now and what lies ahead for MS and the global community to improve the lives of over 2.5 million people around the globe with this autoimmune, neuroinflammatory disease.
COMMITTED TO IMPROVING THE LIVES OF PATIENTS WORLDWIDE
At Celgene, we seek to deliver truly innovative and life-changing drugs for our patients. Our vision as a company is to build a major global biopharmaceutical corporation while focusing on the discovery, the development, and the commercialization of products for the treatment of cancer and other severe, immune, inflammatory conditions.
There are more than 300 clinical trials at major medical centers using compounds from Celgene. Investigational compounds are being studied for patients with incurable hematological and solid tumor cancers, including multiple myeloma, myelodysplastic syndromes, chronic lymphocytic leukemia (CLL), non-Hodgkin’s lymphoma (NHL), triple-negative breast cancer and pancreatic cancer. As committed as we are to clinical accomplishment, we are equally committed to patient support, which is a guiding principle at Celgene. We believe all who can benefit from our discoveries should have the opportunity to do so. Celgene puts patients first with industry-leading programs that provide information, support and access to our innovative therapies.
Celgene is committed to advancing research to deliver life-changing solutions for people living with a wide range of debilitating and chronic diseases, including Multiple Sclerosis (MS). Our teams and experts in the field share our excitement for what we’re doing now and what lies ahead for MS and the global community to improve the lives of over 2.5 million people around the globe with this autoimmune, neuroinflammatory disease.
COMMITTED TO IMPROVING THE LIVES OF PATIENTS WORLDWIDE
At Celgene, we seek to deliver truly innovative and life-changing drugs for our patients. Our vision as a company is to build a major global biopharmaceutical corporation while focusing on the discovery, the development, and the commercialization of products for the treatment of cancer and other severe, immune, inflammatory conditions.
There are more than 300 clinical trials at major medical centers using compounds from Celgene. Investigational compounds are being studied for patients with incurable hematological and solid tumor cancers, including multiple myeloma, myelodysplastic syndromes, chronic lymphocytic leukemia (CLL), non-Hodgkin’s lymphoma (NHL), triple-negative breast cancer and pancreatic cancer. As committed as we are to clinical accomplishment, we are equally committed to patient support, which is a guiding principle at Celgene. We believe all who can benefit from our discoveries should have the opportunity to do so. Celgene puts patients first with industry-leading programs that provide information, support and access to our innovative therapies.
Jul 02, 2019
Celgene is committed to advancing research to deliver life-changing solutions for people living with a wide range of debilitating and chronic diseases, including Multiple Sclerosis (MS). Our teams and experts in the field share our excitement for what we’re doing now and what lies ahead for MS and the global community to improve the lives of over 2.5 million people around the globe with this autoimmune, neuroinflammatory disease.
COMMITTED TO IMPROVING THE LIVES OF PATIENTS WORLDWIDE
At Celgene, we seek to deliver truly innovative and life-changing drugs for our patients. Our vision as a company is to build a major global biopharmaceutical corporation while focusing on the discovery, the development, and the commercialization of products for the treatment of cancer and other severe, immune, inflammatory conditions.
There are more than 300 clinical trials at major medical centers using compounds from Celgene. Investigational compounds are being studied for patients with incurable hematological and solid tumor cancers, including multiple myeloma, myelodysplastic syndromes, chronic lymphocytic leukemia (CLL), non-Hodgkin’s lymphoma (NHL), triple-negative breast cancer and pancreatic cancer. As committed as we are to clinical accomplishment, we are equally committed to patient support, which is a guiding principle at Celgene. We believe all who can benefit from our discoveries should have the opportunity to do so. Celgene puts patients first with industry-leading programs that provide information, support and access to our innovative therapies.
Celgene is committed to advancing research to deliver life-changing solutions for people living with a wide range of debilitating and chronic diseases, including Multiple Sclerosis (MS). Our teams and experts in the field share our excitement for what we’re doing now and what lies ahead for MS and the global community to improve the lives of over 2.5 million people around the globe with this autoimmune, neuroinflammatory disease.
COMMITTED TO IMPROVING THE LIVES OF PATIENTS WORLDWIDE
At Celgene, we seek to deliver truly innovative and life-changing drugs for our patients. Our vision as a company is to build a major global biopharmaceutical corporation while focusing on the discovery, the development, and the commercialization of products for the treatment of cancer and other severe, immune, inflammatory conditions.
There are more than 300 clinical trials at major medical centers using compounds from Celgene. Investigational compounds are being studied for patients with incurable hematological and solid tumor cancers, including multiple myeloma, myelodysplastic syndromes, chronic lymphocytic leukemia (CLL), non-Hodgkin’s lymphoma (NHL), triple-negative breast cancer and pancreatic cancer. As committed as we are to clinical accomplishment, we are equally committed to patient support, which is a guiding principle at Celgene. We believe all who can benefit from our discoveries should have the opportunity to do so. Celgene puts patients first with industry-leading programs that provide information, support and access to our innovative therapies.
Jul 02, 2019
Celgene is committed to advancing research to deliver life-changing solutions for people living with a wide range of debilitating and chronic diseases, including Multiple Sclerosis (MS). Our teams and experts in the field share our excitement for what we’re doing now and what lies ahead for MS and the global community to improve the lives of over 2.5 million people around the globe with this autoimmune, neuroinflammatory disease.
COMMITTED TO IMPROVING THE LIVES OF PATIENTS WORLDWIDE
At Celgene, we seek to deliver truly innovative and life-changing drugs for our patients. Our vision as a company is to build a major global biopharmaceutical corporation while focusing on the discovery, the development, and the commercialization of products for the treatment of cancer and other severe, immune, inflammatory conditions.
There are more than 300 clinical trials at major medical centers using compounds from Celgene. Investigational compounds are being studied for patients with incurable hematological and solid tumor cancers, including multiple myeloma, myelodysplastic syndromes, chronic lymphocytic leukemia (CLL), non-Hodgkin’s lymphoma (NHL), triple-negative breast cancer and pancreatic cancer. As committed as we are to clinical accomplishment, we are equally committed to patient support, which is a guiding principle at Celgene. We believe all who can benefit from our discoveries should have the opportunity to do so. Celgene puts patients first with industry-leading programs that provide information, support and access to our innovative therapies.
Celgene is committed to advancing research to deliver life-changing solutions for people living with a wide range of debilitating and chronic diseases, including Multiple Sclerosis (MS). Our teams and experts in the field share our excitement for what we’re doing now and what lies ahead for MS and the global community to improve the lives of over 2.5 million people around the globe with this autoimmune, neuroinflammatory disease.
COMMITTED TO IMPROVING THE LIVES OF PATIENTS WORLDWIDE
At Celgene, we seek to deliver truly innovative and life-changing drugs for our patients. Our vision as a company is to build a major global biopharmaceutical corporation while focusing on the discovery, the development, and the commercialization of products for the treatment of cancer and other severe, immune, inflammatory conditions.
There are more than 300 clinical trials at major medical centers using compounds from Celgene. Investigational compounds are being studied for patients with incurable hematological and solid tumor cancers, including multiple myeloma, myelodysplastic syndromes, chronic lymphocytic leukemia (CLL), non-Hodgkin’s lymphoma (NHL), triple-negative breast cancer and pancreatic cancer. As committed as we are to clinical accomplishment, we are equally committed to patient support, which is a guiding principle at Celgene. We believe all who can benefit from our discoveries should have the opportunity to do so. Celgene puts patients first with industry-leading programs that provide information, support and access to our innovative therapies.
Jul 02, 2019
Celgene is committed to advancing research to deliver life-changing solutions for people living with a wide range of debilitating and chronic diseases, including Multiple Sclerosis (MS). Our teams and experts in the field share our excitement for what we’re doing now and what lies ahead for MS and the global community to improve the lives of over 2.5 million people around the globe with this autoimmune, neuroinflammatory disease.
COMMITTED TO IMPROVING THE LIVES OF PATIENTS WORLDWIDE
At Celgene, we seek to deliver truly innovative and life-changing drugs for our patients. Our vision as a company is to build a major global biopharmaceutical corporation while focusing on the discovery, the development, and the commercialization of products for the treatment of cancer and other severe, immune, inflammatory conditions.
There are more than 300 clinical trials at major medical centers using compounds from Celgene. Investigational compounds are being studied for patients with incurable hematological and solid tumor cancers, including multiple myeloma, myelodysplastic syndromes, chronic lymphocytic leukemia (CLL), non-Hodgkin’s lymphoma (NHL), triple-negative breast cancer and pancreatic cancer. As committed as we are to clinical accomplishment, we are equally committed to patient support, which is a guiding principle at Celgene. We believe all who can benefit from our discoveries should have the opportunity to do so. Celgene puts patients first with industry-leading programs that provide information, support and access to our innovative therapies.
Celgene is committed to advancing research to deliver life-changing solutions for people living with a wide range of debilitating and chronic diseases, including Multiple Sclerosis (MS). Our teams and experts in the field share our excitement for what we’re doing now and what lies ahead for MS and the global community to improve the lives of over 2.5 million people around the globe with this autoimmune, neuroinflammatory disease.
COMMITTED TO IMPROVING THE LIVES OF PATIENTS WORLDWIDE
At Celgene, we seek to deliver truly innovative and life-changing drugs for our patients. Our vision as a company is to build a major global biopharmaceutical corporation while focusing on the discovery, the development, and the commercialization of products for the treatment of cancer and other severe, immune, inflammatory conditions.
There are more than 300 clinical trials at major medical centers using compounds from Celgene. Investigational compounds are being studied for patients with incurable hematological and solid tumor cancers, including multiple myeloma, myelodysplastic syndromes, chronic lymphocytic leukemia (CLL), non-Hodgkin’s lymphoma (NHL), triple-negative breast cancer and pancreatic cancer. As committed as we are to clinical accomplishment, we are equally committed to patient support, which is a guiding principle at Celgene. We believe all who can benefit from our discoveries should have the opportunity to do so. Celgene puts patients first with industry-leading programs that provide information, support and access to our innovative therapies.
Jul 02, 2019
Celgene is committed to advancing research to deliver life-changing solutions for people living with a wide range of debilitating and chronic diseases, including Multiple Sclerosis (MS). Our teams and experts in the field share our excitement for what we’re doing now and what lies ahead for MS and the global community to improve the lives of over 2.5 million people around the globe with this autoimmune, neuroinflammatory disease.
COMMITTED TO IMPROVING THE LIVES OF PATIENTS WORLDWIDE
At Celgene, we seek to deliver truly innovative and life-changing drugs for our patients. Our vision as a company is to build a major global biopharmaceutical corporation while focusing on the discovery, the development, and the commercialization of products for the treatment of cancer and other severe, immune, inflammatory conditions.
There are more than 300 clinical trials at major medical centers using compounds from Celgene. Investigational compounds are being studied for patients with incurable hematological and solid tumor cancers, including multiple myeloma, myelodysplastic syndromes, chronic lymphocytic leukemia (CLL), non-Hodgkin’s lymphoma (NHL), triple-negative breast cancer and pancreatic cancer. As committed as we are to clinical accomplishment, we are equally committed to patient support, which is a guiding principle at Celgene. We believe all who can benefit from our discoveries should have the opportunity to do so. Celgene puts patients first with industry-leading programs that provide information, support and access to our innovative therapies.
Celgene is committed to advancing research to deliver life-changing solutions for people living with a wide range of debilitating and chronic diseases, including Multiple Sclerosis (MS). Our teams and experts in the field share our excitement for what we’re doing now and what lies ahead for MS and the global community to improve the lives of over 2.5 million people around the globe with this autoimmune, neuroinflammatory disease.
COMMITTED TO IMPROVING THE LIVES OF PATIENTS WORLDWIDE
At Celgene, we seek to deliver truly innovative and life-changing drugs for our patients. Our vision as a company is to build a major global biopharmaceutical corporation while focusing on the discovery, the development, and the commercialization of products for the treatment of cancer and other severe, immune, inflammatory conditions.
There are more than 300 clinical trials at major medical centers using compounds from Celgene. Investigational compounds are being studied for patients with incurable hematological and solid tumor cancers, including multiple myeloma, myelodysplastic syndromes, chronic lymphocytic leukemia (CLL), non-Hodgkin’s lymphoma (NHL), triple-negative breast cancer and pancreatic cancer. As committed as we are to clinical accomplishment, we are equally committed to patient support, which is a guiding principle at Celgene. We believe all who can benefit from our discoveries should have the opportunity to do so. Celgene puts patients first with industry-leading programs that provide information, support and access to our innovative therapies.
Jul 02, 2019
Celgene is committed to advancing research to deliver life-changing solutions for people living with a wide range of debilitating and chronic diseases, including Multiple Sclerosis (MS). Our teams and experts in the field share our excitement for what we’re doing now and what lies ahead for MS and the global community to improve the lives of over 2.5 million people around the globe with this autoimmune, neuroinflammatory disease.
COMMITTED TO IMPROVING THE LIVES OF PATIENTS WORLDWIDE
At Celgene, we seek to deliver truly innovative and life-changing drugs for our patients. Our vision as a company is to build a major global biopharmaceutical corporation while focusing on the discovery, the development, and the commercialization of products for the treatment of cancer and other severe, immune, inflammatory conditions.
There are more than 300 clinical trials at major medical centers using compounds from Celgene. Investigational compounds are being studied for patients with incurable hematological and solid tumor cancers, including multiple myeloma, myelodysplastic syndromes, chronic lymphocytic leukemia (CLL), non-Hodgkin’s lymphoma (NHL), triple-negative breast cancer and pancreatic cancer. As committed as we are to clinical accomplishment, we are equally committed to patient support, which is a guiding principle at Celgene. We believe all who can benefit from our discoveries should have the opportunity to do so. Celgene puts patients first with industry-leading programs that provide information, support and access to our innovative therapies.
Celgene is committed to advancing research to deliver life-changing solutions for people living with a wide range of debilitating and chronic diseases, including Multiple Sclerosis (MS). Our teams and experts in the field share our excitement for what we’re doing now and what lies ahead for MS and the global community to improve the lives of over 2.5 million people around the globe with this autoimmune, neuroinflammatory disease.
COMMITTED TO IMPROVING THE LIVES OF PATIENTS WORLDWIDE
At Celgene, we seek to deliver truly innovative and life-changing drugs for our patients. Our vision as a company is to build a major global biopharmaceutical corporation while focusing on the discovery, the development, and the commercialization of products for the treatment of cancer and other severe, immune, inflammatory conditions.
There are more than 300 clinical trials at major medical centers using compounds from Celgene. Investigational compounds are being studied for patients with incurable hematological and solid tumor cancers, including multiple myeloma, myelodysplastic syndromes, chronic lymphocytic leukemia (CLL), non-Hodgkin’s lymphoma (NHL), triple-negative breast cancer and pancreatic cancer. As committed as we are to clinical accomplishment, we are equally committed to patient support, which is a guiding principle at Celgene. We believe all who can benefit from our discoveries should have the opportunity to do so. Celgene puts patients first with industry-leading programs that provide information, support and access to our innovative therapies.
Jul 02, 2019
Celgene is committed to advancing research to deliver life-changing solutions for people living with a wide range of debilitating and chronic diseases, including Multiple Sclerosis (MS). Our teams and experts in the field share our excitement for what we’re doing now and what lies ahead for MS and the global community to improve the lives of over 2.5 million people around the globe with this autoimmune, neuroinflammatory disease.
COMMITTED TO IMPROVING THE LIVES OF PATIENTS WORLDWIDE
At Celgene, we seek to deliver truly innovative and life-changing drugs for our patients. Our vision as a company is to build a major global biopharmaceutical corporation while focusing on the discovery, the development, and the commercialization of products for the treatment of cancer and other severe, immune, inflammatory conditions.
There are more than 300 clinical trials at major medical centers using compounds from Celgene. Investigational compounds are being studied for patients with incurable hematological and solid tumor cancers, including multiple myeloma, myelodysplastic syndromes, chronic lymphocytic leukemia (CLL), non-Hodgkin’s lymphoma (NHL), triple-negative breast cancer and pancreatic cancer. As committed as we are to clinical accomplishment, we are equally committed to patient support, which is a guiding principle at Celgene. We believe all who can benefit from our discoveries should have the opportunity to do so. Celgene puts patients first with industry-leading programs that provide information, support and access to our innovative therapies.
Celgene is committed to advancing research to deliver life-changing solutions for people living with a wide range of debilitating and chronic diseases, including Multiple Sclerosis (MS). Our teams and experts in the field share our excitement for what we’re doing now and what lies ahead for MS and the global community to improve the lives of over 2.5 million people around the globe with this autoimmune, neuroinflammatory disease.
COMMITTED TO IMPROVING THE LIVES OF PATIENTS WORLDWIDE
At Celgene, we seek to deliver truly innovative and life-changing drugs for our patients. Our vision as a company is to build a major global biopharmaceutical corporation while focusing on the discovery, the development, and the commercialization of products for the treatment of cancer and other severe, immune, inflammatory conditions.
There are more than 300 clinical trials at major medical centers using compounds from Celgene. Investigational compounds are being studied for patients with incurable hematological and solid tumor cancers, including multiple myeloma, myelodysplastic syndromes, chronic lymphocytic leukemia (CLL), non-Hodgkin’s lymphoma (NHL), triple-negative breast cancer and pancreatic cancer. As committed as we are to clinical accomplishment, we are equally committed to patient support, which is a guiding principle at Celgene. We believe all who can benefit from our discoveries should have the opportunity to do so. Celgene puts patients first with industry-leading programs that provide information, support and access to our innovative therapies.
Jul 02, 2019
Celgene is committed to advancing research to deliver life-changing solutions for people living with a wide range of debilitating and chronic diseases, including Multiple Sclerosis (MS). Our teams and experts in the field share our excitement for what we’re doing now and what lies ahead for MS and the global community to improve the lives of over 2.5 million people around the globe with this autoimmune, neuroinflammatory disease.
COMMITTED TO IMPROVING THE LIVES OF PATIENTS WORLDWIDE
At Celgene, we seek to deliver truly innovative and life-changing drugs for our patients. Our vision as a company is to build a major global biopharmaceutical corporation while focusing on the discovery, the development, and the commercialization of products for the treatment of cancer and other severe, immune, inflammatory conditions.
There are more than 300 clinical trials at major medical centers using compounds from Celgene. Investigational compounds are being studied for patients with incurable hematological and solid tumor cancers, including multiple myeloma, myelodysplastic syndromes, chronic lymphocytic leukemia (CLL), non-Hodgkin’s lymphoma (NHL), triple-negative breast cancer and pancreatic cancer. As committed as we are to clinical accomplishment, we are equally committed to patient support, which is a guiding principle at Celgene. We believe all who can benefit from our discoveries should have the opportunity to do so. Celgene puts patients first with industry-leading programs that provide information, support and access to our innovative therapies.
Celgene is committed to advancing research to deliver life-changing solutions for people living with a wide range of debilitating and chronic diseases, including Multiple Sclerosis (MS). Our teams and experts in the field share our excitement for what we’re doing now and what lies ahead for MS and the global community to improve the lives of over 2.5 million people around the globe with this autoimmune, neuroinflammatory disease.
COMMITTED TO IMPROVING THE LIVES OF PATIENTS WORLDWIDE
At Celgene, we seek to deliver truly innovative and life-changing drugs for our patients. Our vision as a company is to build a major global biopharmaceutical corporation while focusing on the discovery, the development, and the commercialization of products for the treatment of cancer and other severe, immune, inflammatory conditions.
There are more than 300 clinical trials at major medical centers using compounds from Celgene. Investigational compounds are being studied for patients with incurable hematological and solid tumor cancers, including multiple myeloma, myelodysplastic syndromes, chronic lymphocytic leukemia (CLL), non-Hodgkin’s lymphoma (NHL), triple-negative breast cancer and pancreatic cancer. As committed as we are to clinical accomplishment, we are equally committed to patient support, which is a guiding principle at Celgene. We believe all who can benefit from our discoveries should have the opportunity to do so. Celgene puts patients first with industry-leading programs that provide information, support and access to our innovative therapies.
Jul 02, 2019
Celgene is committed to advancing research to deliver life-changing solutions for people living with a wide range of debilitating and chronic diseases, including Multiple Sclerosis (MS). Our teams and experts in the field share our excitement for what we’re doing now and what lies ahead for MS and the global community to improve the lives of over 2.5 million people around the globe with this autoimmune, neuroinflammatory disease.
COMMITTED TO IMPROVING THE LIVES OF PATIENTS WORLDWIDE
At Celgene, we seek to deliver truly innovative and life-changing drugs for our patients. Our vision as a company is to build a major global biopharmaceutical corporation while focusing on the discovery, the development, and the commercialization of products for the treatment of cancer and other severe, immune, inflammatory conditions.
There are more than 300 clinical trials at major medical centers using compounds from Celgene. Investigational compounds are being studied for patients with incurable hematological and solid tumor cancers, including multiple myeloma, myelodysplastic syndromes, chronic lymphocytic leukemia (CLL), non-Hodgkin’s lymphoma (NHL), triple-negative breast cancer and pancreatic cancer. As committed as we are to clinical accomplishment, we are equally committed to patient support, which is a guiding principle at Celgene. We believe all who can benefit from our discoveries should have the opportunity to do so. Celgene puts patients first with industry-leading programs that provide information, support and access to our innovative therapies.
Celgene is committed to advancing research to deliver life-changing solutions for people living with a wide range of debilitating and chronic diseases, including Multiple Sclerosis (MS). Our teams and experts in the field share our excitement for what we’re doing now and what lies ahead for MS and the global community to improve the lives of over 2.5 million people around the globe with this autoimmune, neuroinflammatory disease.
COMMITTED TO IMPROVING THE LIVES OF PATIENTS WORLDWIDE
At Celgene, we seek to deliver truly innovative and life-changing drugs for our patients. Our vision as a company is to build a major global biopharmaceutical corporation while focusing on the discovery, the development, and the commercialization of products for the treatment of cancer and other severe, immune, inflammatory conditions.
There are more than 300 clinical trials at major medical centers using compounds from Celgene. Investigational compounds are being studied for patients with incurable hematological and solid tumor cancers, including multiple myeloma, myelodysplastic syndromes, chronic lymphocytic leukemia (CLL), non-Hodgkin’s lymphoma (NHL), triple-negative breast cancer and pancreatic cancer. As committed as we are to clinical accomplishment, we are equally committed to patient support, which is a guiding principle at Celgene. We believe all who can benefit from our discoveries should have the opportunity to do so. Celgene puts patients first with industry-leading programs that provide information, support and access to our innovative therapies.
Jul 02, 2019
Celgene is committed to advancing research to deliver life-changing solutions for people living with a wide range of debilitating and chronic diseases, including Multiple Sclerosis (MS). Our teams and experts in the field share our excitement for what we’re doing now and what lies ahead for MS and the global community to improve the lives of over 2.5 million people around the globe with this autoimmune, neuroinflammatory disease.
COMMITTED TO IMPROVING THE LIVES OF PATIENTS WORLDWIDE
At Celgene, we seek to deliver truly innovative and life-changing drugs for our patients. Our vision as a company is to build a major global biopharmaceutical corporation while focusing on the discovery, the development, and the commercialization of products for the treatment of cancer and other severe, immune, inflammatory conditions.
There are more than 300 clinical trials at major medical centers using compounds from Celgene. Investigational compounds are being studied for patients with incurable hematological and solid tumor cancers, including multiple myeloma, myelodysplastic syndromes, chronic lymphocytic leukemia (CLL), non-Hodgkin’s lymphoma (NHL), triple-negative breast cancer and pancreatic cancer. As committed as we are to clinical accomplishment, we are equally committed to patient support, which is a guiding principle at Celgene. We believe all who can benefit from our discoveries should have the opportunity to do so. Celgene puts patients first with industry-leading programs that provide information, support and access to our innovative therapies.
Celgene is committed to advancing research to deliver life-changing solutions for people living with a wide range of debilitating and chronic diseases, including Multiple Sclerosis (MS). Our teams and experts in the field share our excitement for what we’re doing now and what lies ahead for MS and the global community to improve the lives of over 2.5 million people around the globe with this autoimmune, neuroinflammatory disease.
COMMITTED TO IMPROVING THE LIVES OF PATIENTS WORLDWIDE
At Celgene, we seek to deliver truly innovative and life-changing drugs for our patients. Our vision as a company is to build a major global biopharmaceutical corporation while focusing on the discovery, the development, and the commercialization of products for the treatment of cancer and other severe, immune, inflammatory conditions.
There are more than 300 clinical trials at major medical centers using compounds from Celgene. Investigational compounds are being studied for patients with incurable hematological and solid tumor cancers, including multiple myeloma, myelodysplastic syndromes, chronic lymphocytic leukemia (CLL), non-Hodgkin’s lymphoma (NHL), triple-negative breast cancer and pancreatic cancer. As committed as we are to clinical accomplishment, we are equally committed to patient support, which is a guiding principle at Celgene. We believe all who can benefit from our discoveries should have the opportunity to do so. Celgene puts patients first with industry-leading programs that provide information, support and access to our innovative therapies.
Jul 02, 2019
Celgene is committed to advancing research to deliver life-changing solutions for people living with a wide range of debilitating and chronic diseases, including Multiple Sclerosis (MS). Our teams and experts in the field share our excitement for what we’re doing now and what lies ahead for MS and the global community to improve the lives of over 2.5 million people around the globe with this autoimmune, neuroinflammatory disease.
COMMITTED TO IMPROVING THE LIVES OF PATIENTS WORLDWIDE
At Celgene, we seek to deliver truly innovative and life-changing drugs for our patients. Our vision as a company is to build a major global biopharmaceutical corporation while focusing on the discovery, the development, and the commercialization of products for the treatment of cancer and other severe, immune, inflammatory conditions.
There are more than 300 clinical trials at major medical centers using compounds from Celgene. Investigational compounds are being studied for patients with incurable hematological and solid tumor cancers, including multiple myeloma, myelodysplastic syndromes, chronic lymphocytic leukemia (CLL), non-Hodgkin’s lymphoma (NHL), triple-negative breast cancer and pancreatic cancer. As committed as we are to clinical accomplishment, we are equally committed to patient support, which is a guiding principle at Celgene. We believe all who can benefit from our discoveries should have the opportunity to do so. Celgene puts patients first with industry-leading programs that provide information, support and access to our innovative therapies.
